Search

Biotechnology

Consortium and The Scientist magazine to Host Conference

The National Foundation for Cancer Research, the International Genomics Consortium and The Scientist magazine have joined forces to hold "Biofunding Summit 2003: New Frontiers in Cancer Research" October 16 - 18, 2003 in Phoenix, AZ. Targeted at researchers on the cutting edge of discovery, investors, stock analysts, venture capital groups and, biotech and pharmaceutical executives, the conference will highlight investment opportunities in the Biosciences and provide an informative working session with the world's leading scientists on the inside track to breaking developments in Cancer Research, New Therapies, Novel Treatments and Drug Development.

The NFCR will celebrate its 30th anniversary at this conference by presenting a scientific overview on developing breakthroughs in cancer research and drug development featuring some of the world's leading cancer researchers.

Speakers for the Biofunding Summit Investors Forum on October, 16th include:

-- Jeff Trent, Ph.D., - President, Translational Genomics

Research Institute

-- Dan Von Hoff, M.D. - Director, Arizona Cancer Center and the

NFCR Center for New Therapies Development

-- William Hazeltine Ph.D. - CEO, Human Genome Sciences, Inc.

-- Roy Parker, Ph.D. - Arizona Cancer Center

-- Elizabeth Jaffee, M.D. - Johns Hopkins University

-- Charles Sawyers, M.D. - UCLA

-- Paul Schimmel, Ph.D. - The Scripps Research Institute

-- George Poste, D.V.M., Ph.D. - CEO, Health Technology Networks

-- David Mallery, J.D., MBA - VP, International Genomics

Consortium

-- David Alberts, M.D. - Arizona Cancer Center

"Our goal in creating the Biofunding Summit 2003 is to show the investment community that despite all the doom and gloom you hear in the marketplace, there are some very exciting business opportunities out there, especially as they relate to new research and therapy developments and opportunities in emerging markets," said Franklin C. Salisbury, Jr., president of the National Foundation for Cancer Research. "With some of the greatest scientists in basic science research on tap to highlight their research in a business setting, this should provide an excellent forum for investors seeking news and information about breaking developments."

Scientific presenters on October 17th and 18th include:

-- Bruce Ames, Ph.D., Co-Director, NFCR Center for Genomics and

Nutrition at UC Berkeley

-- Michael Blaese, M.D., Director Fund for Inherited Disease

Research

-- Webster Cavenee, Ph.D., Ludwig Institute for Cancer Research

-- Esther Chang, Ph.D., Georgetown University

-- Yung-Chi Cheng, Ph.D., Yale Medical School

-- Curt Civin, M.D., Johns Hopkins University

-- Stanley Cohen, M.D., Stanford University School of Medicine

-- Ivar Giaever, Ph.D., NL, Rensselaer Polytechnic Institute

-- Daniel Haber, M.D., Massachusetts General Hospital

-- Daniel Von Hoff, M.D., Arizona Cancer Center

-- Waun Ki Hong, M.D., M.D. Anderson Cancer Center

-- Kate Horwitz, Ph.D., Colorado Health Science Center

-- Susan Band Horwitz, Ph.D., Albert Einstein College of

Medicine

-- Laurence Hurley, Ph.D., University of Arizona

-- Wayne Marasco, M.D., Ph.D., Dana Farber Institute and

Director, NFCR Center for Antibody Engineering

-- Larry Marnett, Ph.D., Vanderbilt University School of Medicine

-- W. Graham Richards, Ph.D., University of Oxford and

Director, NFCR Center for Computational Drug Discovery at

Oxford

-- Michael Sporn, M.D., Dartmouth Medical School

-- Bernard Weinstein, M.D., Columbia University

To attend this conference or for more information, please visit the website at www.BioFundingSummit.org or call Silas Deane at (615) 244-8035. Attendance is limited, so please reserve early. Media is highly encouraged to attend and will have access to the entire proceedings.

About the NFCR

Since its founding in 1973, the National Foundation for Cancer Research has spent more than $200 million funding basic science cancer research and cancer education. This worldwide "laboratory without walls" assembles the intellectual power to achieve one of medicine's greatest goals: a cure for cancer. Prevention, new treatments, and a cure depend on understanding cancer's genetic origins; NFCR is dedicated to funding scientists who are discovering cancer's molecular mysteries and translating these discoveries into therapies that hold the only real hope for curing cancer. For more information, please visit NFCR's website at www.NFCR.org or call (800) 321-CURE.

About the International Genomics Consortium

The International Genomics Consortium is a non-profit medical research foundation established to expand upon the discoveries of Human Genome Project and other systematic sequencing efforts by combining world-class genomic research, bioinformatics, and diagnostic technologies in the fight against cancer and other complex genetic diseases. For more information, visit www.Intgen.org.

About The Scientist

The Scientist is an international news magazine published in print and on the Web. It reports on and analyzes the issues and events that impact the world of life scientists. The Scientist provides a unifying forum for discussion of the topics -news, research, profession and technology - that drive scientific progress. Comprehensive and topical, it serves as an ally and a guide in today's exciting and competitive research environment. For more information, visit www.The-Scientist.com.

Research Institute

-- Dan Von Hoff, M.D. - Director, Arizona Cancer Center and the

NFCR Center for New Therapies Development

-- William Hazeltine Ph.D. - CEO, Human Genome Sciences, Inc.

-- Roy Parker, Ph.D. - Arizona Cancer Center

-- Elizabeth Jaffee, M.D. - Johns Hopkins University

-- Charles Sawyers, M.D. - UCLA

-- Paul Schimmel, Ph.D. - The Scripps Research Institute

-- George Poste, D.V.M., Ph.D. - CEO, Health Technology Networks

-- David Mallery, J.D., MBA - VP, International Genomics

Consortium

-- David Alberts, M.D. - Arizona Cancer Center

-- Bruce Ames, Ph.D., Co-Director, NFCR Center for Genomics and

Nutrition at UC Berkeley

-- Michael Blaese, M.D., Director Fund for Inherited Disease

Research

-- Webster Cavenee, Ph.D., Ludwig Institute for Cancer Research

-- Esther Chang, Ph.D., Georgetown University

-- Yung-Chi Cheng, Ph.D., Yale Medical School

-- Curt Civin, M.D., Johns Hopkins University

-- Stanley Cohen, M.D., Stanford University School of Medicine

-- Ivar Giaever, Ph.D., NL, Rensselaer Polytechnic Institute

-- Daniel Haber, M.D., Massachusetts General Hospital

-- Daniel Von Hoff, M.D., Arizona Cancer Center

-- Waun Ki Hong, M.D., M.D. Anderson Cancer Center

-- Kate Horwitz, Ph.D., Colorado Health Science Center

-- Susan Band Horwitz, Ph.D., Albert Einstein College of

Medicine

-- Laurence Hurley, Ph.D., University of Arizona

-- Wayne Marasco, M.D., Ph.D., Dana Farber Institute and

Director, NFCR Center for Antibody Engineering

-- Larry Marnett, Ph.D., Vanderbilt University School of Medicine

-- W. Graham Richards, Ph.D., University of Oxford and

Director, NFCR Center for Computational Drug Discovery at

Oxford

-- Michael Sporn, M.D., Dartmouth Medical School

-- Bernard Weinstein, M.D., Columbia University

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.